One sentence summary: Unlike tubercle bacilli, BCG is unable to secrete cyclic di-AMP and induce type I interferon in infected macrophages, which is informative for development of a better vaccine against tuberculosis. Editor: Patrick Brennan
INTRODUCTION
Tuberculosis (TB) remains a major threat to public health. However, the pathogenesis of the etiologic agent, Mycobacterium tuberculosis (Mtb), is still not fully understood. Mycobacterium bovis bacillus Calmette-Guerin (BCG) is the only available TB vaccine, but inadequately controls the TB epidemic. The molecular basis of BCG's limitation in TB prevention is still elusive. Thus, it is essential to understand how Mtb and BCG interact with the host in order to develop a better vaccination strategy.
Cyclic di-AMP (c-di-AMP) was first recognized as a new second messenger in 2008 (Witte et al. 2008) . This di-nucleotide is produced from ATP by diadenylate cyclases and cleaved to pApA or AMP by distinct c-di-AMP phosphodiesterases (Bai et al. 2013; Corrigan et al. 2013; Manikandan et al. 2014) . The diadenylate cyclase domain is widespread in bacteria and archaea, but has not been found in eukaryotic cells (Romling 2008; Corrigan et al. 2013) . Presence of active diadenylate cyclase has been experimentally demonstrated in several bacterial species (Witte et al. 2008; Woodward, Iavarone and Portnoy 2010; Corrigan et al. 2011; Kamegaya, Kuroda and Hayakawa 2011; Luo and Helmann 2012; Bai et al. 2013; Barker et al. 2013; Mehne et al. 2013) , and the enzyme is essential for bacterial viability of Bacillus subtilis (Luo and Helmann 2012, Mehne et al. 2013) , Staphylococcus aureus (Corrigan et al. 2011) , Streptococcus pneumoniae (Bai et al. 2013) and Listeria monocytogenes at certain growth conditions (Woodward et al. 2010; Witte et al. 2013; Whiteley, Pollock and Portnoy 2015) . Additionally, c-di-AMP is associated with bacterial infections (Cron et al. 2011; Pozzi et al. 2012; Schwartz et al. 2012; Yamamoto et al. 2012; Witte et al. 2013; Dey et al. 2015) , peptidoglycan homeostasis (Corrigan et al. 2011; Luo and Helmann 2012) , antibiotic resistance (Banerjee et al. 2010; Corrigan et al. 2011; Griffiths and O'Neill 2012; Luo and Helmann 2012; Witte et al. 2013 ) and bacterial morphology and/or biofilm formation (Corrigan et al. 2011; Pozzi et al. 2012; Bai et al. 2013; Yang et al. 2014; Peng et al. 2016) . Furthermore, c-di-AMP produced by L. monocytogenes, Chlamydia trachomatis and Mtb promotes a type I interferon (IFNα/β) response mediated by host effectors STING and DDX41 through an IRF-3-regulated signaling pathway (Woodward et al. 2010; Burdette et al. 2011; Jin et al. 2011; Sauer et al. 2011; Bowie 2012; Parvatiyar et al. 2012; Barker et al. 2013; Yang et al. 2014; Dey et al. 2015) .
We previously identified DisA and CnpB as diadenylate cyclase and c-di-AMP phosphodiesterase, respectively, in Mtb (Bai et al. 2012; Yang et al. 2014) and demonstrated that deletion of disA abolished Mtb's c-di-AMP production. More interestingly, deletion of cnpB elevated bacterial c-di-AMP accumulation and secretion, induced a strong host type I IFN response and significantly attenuated the virulence in a mouse infection model (Yang et al. 2014; Dey et al. 2017) . A similar observation was reported with a disA-overexpressing Mtb strain (Dey et al. 2015) . Together, these observations suggest that elevated c-di-AMP levels play a protective role during Mtb infection.
It has been shown that both BCG and Mtb RD1 (region of difference 1) fail to trigger a relevant host type I IFN response compared to Mtb wildtype (WT) (Novikov et al. 2011; Dey et al. 2015) . Interestingly, addition of type I IFN improves BCG's immunogenicity in vitro (Giacomini et al. 2009) , and boosting BCG vaccination with type I IFN protects mice against Mycobacterium lepraemurium infection (Guerrero et al. 2015) . Additionally, a recombinant BCG vaccine with ESAT-6 secretion complex-1 (ESX-1) of Mycobacterium marinum induces type I IFN and enhances T cell immunity against Mtb challenge (Groschel et al. 2017 ). These observations implicate that the defect in type I IFN induction is one of the reasons for the failure of BCG. It has been well established that Mtb ESX-1 is required for the type I IFN response both in vitro and in vivo (Stanley et al. 2007) . ESX-1 is partially encoded by genes in RD1, a 9.5-kb locus in the Mtb genome but missing in BCG (Mahairas et al. 1996; Behr et al. 1999; Gordon et al. 1999) . RD1 contains nine genes, including esxA and esxB, which encode for ESAT-6 and CFP-10, respectively. Earlier reports support that ESAT-6 is essential for rupturing the phagosomal membrane and releasing the mycobacterial components into the cytosol of the host cell (van der Wel, Hava and Houben 2007; Houben et al. 2012; Simeone et al. 2012 Simeone et al. , 2015 . However, a recent study suggests that ESX-1 but not ESAT-6 is needed to permeabilize the phagosomal membrane (Conrad et al. 2017) . Nonetheless, it is unknown whether this process is required for the phagosometo-cytosol translocation of c-di-AMP as a small molecule produced by Mtb.
In the current study, we demonstrate that c-di-AMP can be secreted by Mtb cnpB but not BCG cnpB. Both c-di-AMP secretion machinery and RD1 are required for Mtb to induce the cdi-AMP-mediated host response by the infected macrophages, which is observed from a type I IFN response in infected macrophages. Since type I IFN improves BCG's immunogenicity, amending BCG to induce type I IFN response based on the c-di-AMP signaling network of Mtb will likely improve BCG's efficacy.
MATERIALS AND METHODS

Bacterial strains and growth conditions
The bacterial strains used in this study are listed in Table 1 . Mtb H37Rv, BCG (Pasteur strain; Trudeau Institute) and their derivatives were grown at 37
• C in mycomedium (Middlebrook 7H9 medium (BD) supplemented with 0.5% glycerol, 10% oleic acid-albumin-dextrose-catalase (OADC), and 0.05% Tween-80), Sauton's medium (Bai, Schaak and McDonough 2009) Kanamycin at 25 μg/ml, hygromycin at 50 μg/ml or zeocin at 100 μg/ml were added when necessary.
Construction and complementation of mutants in Mtb and BCG
BCG disA and cnpB were generated by using phages prepared with pMBC1206 and pGB132 (Table 1) , respectively, which were previously used to delete disA and cnpB in Mtb by using a phagebased approach (Yang et al. 2014) . The mutants were selected with plates containing 50 μg/ml hygromycin and screened by PCR using primers as listed in Table S1 , Supporting Information. Subsequently, disA and cnpB of BCG were transformed with pGB086 and pGB120, respectively, for complementation similar to what we have performed to complement the relevant mutants in Mtb (Yang et al. 2014) . The hygromycin resistance marker in both cnpB of Mtb and BCG was unmarked using pYO11 (provided by Dr Jeffery Cox) (Rosenberg et al. 2015) . Briefly, hygromycin-resistant cnpB was transformed with pYO11 and selected with Middlebrook 7H10 plates containing 100 μg/ml zeocin. Zeocin-resistant transformants were passaged in mycomedium without antibiotics for at least three times to cure pYO11. Bacteria sensitive to both hygromycin and zeocin were confirmed as unmarked cnpB by PCR using primers JY213 and JY214. The PCR products from the unmarked strains exhibit a significantly reduced size compared to those from the WT and the hygromycin-resistant cnpB strains. disA cnpB of Mtb and BCG were then generated from the unmarked cnpB strains by transducing the phage for deletion of disA similarly as we previously described (Yang et al. 2014) . Mtb RD1 and cnpB RD1 were generated using the phagebased method (Yang et al. 2014) . Briefly, a phage used to delete RD1 (provided by Dr William Jacobs, Jr) (Hsu et al. 2003) was transduced into WT and the unmarked cnpB mutant of Mtb. Replacement of RD1 with a hygromycin resistance marker in both genetic backgrounds was confirmed by PCR with primers JY407, JY002, JY003 and JY408 (Table S1 , Supporting Information). Deletion of RD1 was further verified by PCR amplification of an esxA fragment using primers KM1325 and KM1326 (Table  S1 , Supporting Information). WT control exhibits a 250-bp product, whereas the mutants lack this fragment.
Transformation of BCG strains with cosmid pRD1
BCG WT and cnpB were transformed with cosmid pRD1 (provided by Dr Keith Derbyshire) using electroporation at 2.5 kV, 25 μF and 1000 (Flint et al. 2004) . This cosmid harbors a 32-kb segment (Rv3861-Rv3885) flanking the 9.5-kb RD1 locus (Rv3871-Rv3879c) (Pym et al. 2003) . The recombinant strains were selected on a Middlebrook 7H10 plate containing 50 μg/ml hygromycin and were verified by PCR using primers specific to whiB6 (Rv3862), esxA (Rv3875) and Rv3879c (Table S1 , Supporting Information). DNA isolated from BCG WT was used as a negative control for the PCR reaction.
Detection of c-di-AMP
c-di-AMP was extracted and measured by using an enzymelinked immunosorbent assay (ELISA) as we described earlier (Underwood et al. 2014; Yang et al. 2014) . Briefly, each bacterial strain was grown in 5 ml of Sauton's medium for 7 days. The optical density at 600 nm (OD 600 ) was determined. Bacteria were harvested by centrifugation, and the supernatant was used for secreted c-di-AMP determination. Each bacterial pellet was resuspended in 0.5 ml 50 mM Tris-HCl (pH 8.0) and disrupted with 1 mm glass beads using a mini bead-beater (BioSpec). Bacterial debris was removed by centrifugation and the supernatant was boiled for 5 min and subsequently used as the bacterial c-di-AMP sample. c-di-AMP levels were quantified by using the competitive ELISA (Underwood et al. 2014; Yang et al. 2014) . Results of both bacterial and secreted samples were normalized by respective OD 600 readings. (Jin et al. 2008) and Herbert Virgin (Schoggins et al. 2014) , respectively. The knockout mice were bred and maintained in the Animal Resources Facility at Albany Medical College. Bone marrow-derived macrophages (BMDMs) were generated as previously described (Jin et al. 2011) , which was approved by the Albany Medical College IACUC. Briefly, bone marrow cells were harvested from mouse femurs and cultured in complete RPMI-1640 supplemented 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 mM sodium pyruvate, 1× HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], 1× nonessential amino acids, 50 μM β-mercaptoethanol, 100 U/ml penicillin, 100 μg/ml streptomycin and 20 ng/ml M-CSF. All reagents were purchased from Gibco. BMDM cells were seeded in 12-well plates at 5 × 10 5 cells/ml and 0.5 ml/well in the supplemented RPMI-1640 medium without antibiotics. Cells were infected with Mtb, BCG or their derivatives at a multiplicity of infection (MOI) of 2:1. At 4 h postinfection, infection medium was replaced with fresh complete RPMI-1640 medium after washing thrice with PBS. At 1 and 2 days post-infection, culture supernatant was collected to determine cytokine production.
Preparation and infection of BMDMs
Cytokine detection
IFN-β in tissue culture supernatant was detected using ELISA with a Verikine-HS Mouse IFN-β serum ELISA kit (PBL Assay Science) following the manufacturer's manual similarly as we reported earlier (Yang et al. 2014) .
Statistical analysis
Comparisons of the c-di-AMP levels between WT, BCG and their derivatives were analyzed using a two-tailed t-test performed using Prism 5 (GraphPad Software). IFN-β levels were analyzed using a two-way ANOVA (GraphPad Software). P values of <0.05 were considered to be statistically significant. For IFN-β levels, each bacterial mutant was compared to the parental strain in infection of the BMDMs isolated from the same mouse.
RESULTS
DisA is likely the sole diadenylate cyclase in Mtb
Increasing evidence has revealed that c-di-AMP participates in multiple critical intracellular bioprocesses. It has been reported that diadenylate cyclase-encoding genes are essential for several Gram-positive bacteria including S. aureus (Corrigan et al. 2011) , S. pneumoniae (Bai et al. 2013) and L. monocytogenes (Woodward et al. 2010; Witte et al. 2013) , each of which possesses a single diadenylate cyclase. A recent study has revealed that diadenylate cyclase is conditionally essential for L. monocytogenes when the bacterium is grown in rich media or within host cells, but not in minimal media that do not trigger (p)ppGpp synthesis (Whiteley et al. 2015) . B. subtilis encodes three diadenylate cyclases, which can be individually disrupted but cannot be deleted together when bacteria were grown in regular cultural media (Luo and Helmann 2012; Mehne et al. 2013) . A triple mutant of B. subtilis diandenylate cyclases was generated only in low K + media (Gundlach et al. 2017) . DisA is the only known protein that possesses a diadenylate cyclase domain in Mtb. Surprisingly, we could easily delete disA from the Mtb genome, and the mutant grew well in various mycobacterial culture media and intracellularly (Yang et al. 2014) . We hypothesized that either the role of c-di-AMP in Mtb differs from that in Gram-positive bacteria or Mtb encodes more than one diadenylate cyclase, similar to B. subtilis. We generated a disA cnpB mutant in Mtb, which was unable to accumulate detectable c-di-AMP, similar to disA (Fig. 1A) . This result indicates that DisA is very likely the sole diadenylate cyclase in this pathogen and that c-di-AMP is not required for the viability of Mtb. The role of c-di-AMP in Mtb is distinct from that in the Gram-positive bacteria that have been characterized for c-di-AMP to date.
BCG differs from Mtb in c-di-AMP secretion
In order to explore c-di-AMP-mediated biological differences between Mtb and BCG, we generated disA, cnpB and disA cnpB mutants in BCG and compared these mutants with WT BCG as well as the Mtb strains in c-di-AMP production and secretion. We detected similar levels of c-di-AMP within BCG strains compared to those within the relevant Mtb strains ( Fig. 1A and B) . In contrast, secreted c-di-AMP was detected from Mtb cnpB, but not BCG cnpB ( Fig. 1C and D) . This result indicates that both DisA and CnpB are functional in BCG; however, the c-di-AMP secretion machinery of BCG is defective, which differs from Mtb. In L. monocytogenes, both MdrM and MdrT are capable of secreting c-di-AMP (Woodward et al. 2010; Schwartz et al. 2012; Tadmor et al. 2014) . These proteins are multidrug efflux pumps. We compared all the efflux pump-encoding genes of Mtb to those in the BCG genome by sequence alignment. Most efflux pumps of BCG are nearly identical in amino acid sequence to their orthologs in Mtb except the proteins encoded by Rv3877 and Rv1877 (Cole et al. 1998; Brosch et al. 2007) . Rv3877 is located in the RD1 region (Behr et al. 1999) , which is absent in the BCG genome. In order to determine whether RD1 plays a role in c-di-AMP secretion, we deleted RD1 in both WT and cnpB of Mtb and examined c-di-AMP secretion by the mutants. As a result, these mutants displayed no differences in c-di-AMP accumulation or secretion compared to their parental strains (Fig. S1A, Supporting Information) . Consistently, we transformed either a plasmid expressing Rv3877 (not shown) or a cosmid flanking RD1 (pRD1) into BCG cnpB (Fig. S1B , Supporting Information), and these recombinant strains were unable to secrete c-di-AMP. These observations suggest that Rv3877 does not play a role in c-di-AMP secretion. Additionally, the Rv1877 ortholog in BCG introduces a frameshift due to a single base insertion ( * -c), which splits Rv1877 into two segments (Fig. S2 , Supporting Information). We expressed Mtb Rv1877 in BCG cnpB but could not detect secreted c-di-AMP from this recombinant strain (not shown), indicating that either Mtb utilizes other efflux pumps or it has a different mechanism for c-di-AMP secretion compared to L. monocytogenes.
Both c-di-AMP secretion machinery and RD1 are needed in the c-di-AMP-mediated type I IFN response
It is known that BCG and Mtb RD1 mutant are defective in inducing a type I IFN response (Giacomini et al. 2009; Dey et al. 2015) . Interestingly, it has been shown that type I IFN improves BCG's immunogenicity (Giacomini et al. 2009) , and boosting BCG D) , respectively, were grown in Sauton's broth for 7 days. Bacteria were harvested by centrifugation. The c-di-AMP levels in the supernatant (secreted) and in the lysate prepared from the pellet (bacterial) were determined using ELISA. The data shown are the means of three independent experiments. The error bars indicate the standard errors of mean (SEMs). * P < 0.05; * * P < 0.01; * * * P < 0.001. P values are statistical analyses resulted from a two-tailed t-test. Note the detectable limit of the assay is ∼10 nM. disA/C and cnpB/C are the complemented strains for disA and cnpB, respectively.
vaccination with type I IFN provides better protection in mice challenged with M. lepraemurium (Guerrero et al. 2015) . Therefore, modifying BCG to be able to induce optimal levels of type I IFN response might improve BCG's efficacy. In this study, we explored the molecular basis for BCG's failure in the type I IFN response. It has been well established that c-di-AMP produced by intracellular bacteria stimulates a type I IFN response (Woodward et al. 2010; Sauer et al. 2011; Schwartz et al. 2012; Barker et al. 2013; Archer, Durack and Portnoy 2014; Dey et al. 2015) . Our previous study revealed that Mtb cnpB secretes a large amount of c-di-AMP and induces high levels of IFN-β during a macrophage infection (Yang et al. 2014) , which is consistent with a recent report (Dey et al. 2017 ) and the observation from a disA-overexpressing Mtb strain (Dey et al. 2015) . Several recent reports show that during Mtb infection, Mtb DNA rather than c-di-AMP is a major trigger for the type I IFN response, which is also cGAS-dependent (Collins et al. 2015; Wassermann et al. 2015; Watson et al. 2015) . Therefore, the IFN-β response we previously observed is either due to enhanced DNA secretion or partially contributed by the large amount of c-di-AMP. Furthermore, it has been shown that RD1 is required for releasing mycobacterial components from the phagosome into the cytosol (Conrad et al. 2017) . However, it is unknown whether Mtb-secreted c-di-AMP can be directly released from the phagosome or it is dependent upon RD1. Thus, we sought to address two major questions: (i) Is the elevated type I IFN response to Mtb cnpB infection mediated by DNA or c-di-AMP? and (ii) Is RD1 required for the cnpB-induced type I IFN response?
In this study, we isolated BMDMs from WT, STING −/− and cGAS −/− mice and examined the IFN-β production by the cells infected with Mtb, BCG and their derivatives, respectively. Similar results were observed between the samples collected at 1 day ( Fig. 2 ) and 2 day (not shown) post-infection. From BMDMs of WT mice, Mtb disA stimulated less IFN-β than the WT strain ( Fig. 2A) . In contrast, Mtb cnpB induced a considerably larger amount of IFN-β than WT, similarly as we reported earlier (Yang et al. 2014) . Moreover, disA cnpB failed to trigger a type I response ( Fig. 2A) . These results indicate an association between c-di-AMP and the type I IFN response. By comparing infected BMDMs isolated from WT, STING −/− and cGAS −/− mice, we found that IFN-β production induced by Mtb WT and cnpB was nearly abolished in the infected STING −/− cells, and cGAS −/− cells exhibited reduced IFN-β production in a c-di-AMP-dependent pattern (Fig. 2) . This result is consistent with a recent report by Dey et al. using a transposon mutant of cnpB (Dey et al. 2017) . Overall, our results indicate that DNA is a major player of the Mtbinduced type I IFN response, which is consistent with several recent reports (Collins et al. 2015; Wassermann et al. 2015; Watson et al. 2015) . Meanwhile, c-di-AMP also contributes directly to a substantial type I IFN response during Mtb infection, which is also coherent with an earlier observation (Dey et al. 2015) . h. After thoroughly washing, cells were incubated for 24 h, and the supernatant was then collected to determine IFN-β. The data shown are the means of three independent experiments. The error bars indicate the SEMs. * P < 0.05; * * P < 0.01; * * * P < 0.001. P values are statistical analyses resulted from a two-tailed t-test to compare each bacterial mutant to the parental strain in infection of the BMDMs isolated from the same mouse.
RD1 has been shown to be essential for Mtb to permeabilize the phagosomal membrane of the infected cells (de Jonge et al. 2007; Stanley et al. 2007; De Leon et al. 2012) . In this study, we explored whether RD1 is required for the Mtb cnpB-induced type I IFN response, as c-di-AMP is a small molecule, which may penetrate phagosomal membrane directly. Remarkably, IFN-β production was dramatically reduced by infection with RD1 generated in either the WT or the cnpB genetic background (Fig. 2) , even though cnpB RD1 still secretes c-di-AMP as potently as the cnpB mutant (Fig. S1, Supporting Information) . This result indicates that RD1 is required for the Mtb cnpBinduced type I IFN response. With BCG strains, BCG WT failed to trigger an IFN-β response, which is consistent with other reports (Giacomini et al. 2009; Dey et al. 2015) . Furthermore, neither BCG cnpB nor BCG cnpB bearing the pRD1 cosmid elicited a type I IFN response, suggesting that the absence of RD1 is not the only reason for BCG's defect in the type I IFN induction. Collectively, we conclude that both the c-di-AMP secretion machinery and RD1 are required for c-di-AMP-mediated response in the infected macrophages.
DISCUSSION
In this study, we demonstrate that both the c-di-AMP secretion machinery and RD1 are required for Mtb to induce the host type I IFN response. We propose a model for this response based on our observations together with several earlier reports (Manzanillo et al. 2012; Collins et al. 2015; Wassermann et al. 2015; Watson et al. 2015; Conrad et al. 2017) (Fig. 3) . In this model, cdi-AMP is secreted from Mtb into an infected phagosome by a currently unknown mechanism. Proteins encoded by the ESX-1 facilitate c-di-AMP releasing from the phagosome into the cytosol of the infected macrophage. Meanwhile, Mtb DNA is also released through the permeabilized phagosome into the cytosol and activates cGAS to produce cyclic GMP-AMP (cGAMP). Both c-di-AMP and cGAMP are then sensed by STING, which induces the type I IFN response.
Three mycobacterial components have been shown to induce a type I IFN response: (i) c-di-AMP directly detected by STING (Yang et al. 2014; Dey et al. 2015) ; (ii) DNA through a cGAS-STING signaling pathway (Manzanillo et al. 2012; Collins et al. 2015; Wassermann et al. 2015; Watson et al. 2015) ; and (iii) peptidoglycan through an NOD2 signaling pathway (Pandey et al. 2009 ). We have demonstrated that the elevated IFN-β production induced by Mtb cnpB is unlikely resulted from the NOD2 signaling pathway by using BMDMs isolated from NOD2 −/− mice (Yang et al. 2014) . In this study, we show that the majority of IFN-β induced by Mtb cnpB is elicited by the DNA-sensing pathway through cGAS, indicating that cnpB enhanced Mtb DNA release after 1 and 2 days post-infection, which is consistent with the recent reports regarding the host response to mycobacterial DNA (Collins et al. 2015; Wassermann et al. 2015; Watson et al. 2015) and c-di-AMP-mediated type I IFN induction by L. monocytogenes (Hansen et al. 2014) . Additionally, Mtb cnpB also induces a small amount of IFN-β in a STING-dependent but cGAS-independent manner, suggesting that this proportion of IFN-β is directly stimulated by c-di-AMP. As we pointed out in an earlier report, secreted c-di-AMP that we detected from Mtb cnpB is unlikely due to bacterial lysis (Yang et al. 2014) . Meanwhile, mycobacterial DNA sensed by cGAS has also been considered to originate from living but not degraded bacteria (Majlessi and Brosch 2015) . Based on the results of the type I IFN response of BMDMs isolated from WT, STING −/− and cGAS −/− mice, c-di-AMP possibly enhances DNA secretion by Mtb. It is also likely that Mtb DNA and c-di-AMP share the same secretion machinery, which we will explore in the future. Several studies have demonstrated that type I IFN increased host susceptibility to Mtb infection (Manca et al. 2001 (Manca et al. , 2005 Antonelli et al. 2010; Dorhoi et al. 2014) . On the other hand, there is also evidence that type I IFN is protective in certain circumstances (Desvignes, Wolf and Ernst 2012) . Thus, it is likely that a balance of this cytokine is required for optimal protection during Mtb infection (Wiens and Ernst 2016) . Nonetheless, the recombinant BCG vaccine with ESX-1 of M. marinum induces type I interferon and stronger T cell response, which provides better protection against Mtb challenge (Groschel et al. 2017) , suggesting that the type I IFN induced during vaccination is beneficial to the host.
Most interestingly, we found that BCG cnpB was unable to secrete c-di-AMP. This observation is highly significant from the vaccine perspective, since the limitation of BCG in the prevention of the TB epidemic is still not fully understood. Manipulation of c-di-AMP secretion from BCG and release from the phagosome into host cytosol during vaccination will enable BCG to induce substantial levels of type I IFN locally, which might improve BCG's immunogenicity based on multiple vaccine studies (Giacomini et al. 2009; Guerrero et al. 2015; Conrad et al. 2017; Groschel et al. 2017) . This 'localized' response could be optimized by the levels of c-di-AMP production and should not significantly enhance the susceptibility of Mtb infection. Furthermore, c-di-AMP has been explored as an adjuvant for vaccinations and induces strong humoral and cellular immune responses (Ebensen et al. 2011; Sanchez et al. 2014; Skrnjug et al. 2014) . Therefore, an engineered BCG based on cnpB and amended c-di-AMP secretion machinery may elevate the vaccine efficacy. In our future studies, we will generate and examine such recombinant BCG strains as novel vaccines in protection against TB.
